Chlorprothixen Stevkbrief (Prescribing Information)
Note: The evidence provided does not contain prescribing information for chlorprothixene (Truxal/Taractan). The available FDA drug label and clinical guidelines reference chlorpromazine, not chlorprothixene, which are distinct antipsychotic medications despite similar names. 1
Available Evidence on Chlorprothixene
Historical Clinical Profile
- Chlorprothixene is a thioxanthene-class neuroleptic that was first marketed in 1959 under the trade names Taractan and Truxal, representing the first neuroleptic of the thioxanthene group. 2
- A comprehensive 20-year literature review encompassing 11,487 patients demonstrated chlorprothixene functions as a broad-spectrum neuroleptic with good therapeutic effects and notably low rates of extrapyramidal symptoms (only 1.02% of patients, with tardive dyskinesia occurring in just 0.05%). 2
Dosing Information from Clinical Studies
- Pediatric premedication: 1-2 mg/kg orally (as 4% solution) or 1 mg/kg intramuscularly, administered 2 hours before anesthesia induction for optimal effect. 3
- Chronic pain management: 50 mg every 6 hours for 5 days (inpatient setting only) showed pain alleviation in one-third of patients with post-herpetic neuralgia, though prominent side effects occurred during treatment. 4
- Maintenance therapy: Doses ranging from 120-600 mg daily have been used in outpatient psychiatric settings, with plasma uric acid levels serving as a reliable compliance indicator (chlorprothixene consistently lowers uric acid levels, which normalize within 7 days of discontinuation). 5
Safety Considerations
- Cardiometabolic risks: Low-dose chlorprothixene use is associated with increased risk of diabetes (hazard ratio 1.34 when restricted to treatment period) and major adverse cardiovascular events (hazard ratio 1.12), particularly stroke (hazard ratio 1.21), compared to low-dose quetiapine. 6
- Dose-dependent risks: Cumulative doses ≥6000 mg are associated with increased diabetes risk (OR 1.15-1.63), while cumulative doses ≥1500 mg are associated with increased cardiovascular event risk (OR 1.10-1.85). 6
- Hypotension: More frequent with intramuscular versus oral administration, particularly in pediatric populations. 3
Drug Interactions
- Chlorprothixene can cause drug-drug interactions when combined with other antipsychotics affecting the same metabolic pathways, potentially leading to additive or reductive effects on plasma concentrations and side effect severity (specifically documented with risperidone combinations). 7
Critical Caveat
The FDA drug label information provided in the evidence 1 pertains to chlorpromazine, NOT chlorprothixene. These are different medications with distinct pharmacological profiles, and their prescribing information should not be conflated. For official chlorprothixene prescribing information, consult the specific product labeling for Truxal or Taractan where available.